Breakthrough in Cancer Detection: New Liquid Biopsy Technology Outperforms Existing Methods

Researchers at the University of Chicago have developed a novel liquid biopsy technology that uses RNA to detect cancer, achieving an unprecedented accuracy rate of 95% in identifying early colorectal cancer. This innovative method surpasses existing non-invasive detection methods, which have an accuracy rate of around 90% for late-stage cancer but only 50% for early-stage cancer. The study, published in the latest issue of Nature Biotechnology, marks a significant advancement in cancer detection and treatment.

Key Takeaways:

The new liquid biopsy technology uses RNA instead of traditional DNA to detect cancer, allowing for earlier detection and higher accuracy.
The method analyzes circulating free RNA (cfRNA) in patient blood samples, which contains clues about gene activity and cell behavior.
Billions of bacteria live in the human digestive system, and the behavior of these microorganisms changes as cancerous tumors develop, which can be detected through RNA modification levels.
The new method has an accuracy rate of nearly 95% in detecting early-stage cancer, compared to less than 50% for existing non-invasive detection methods.
The technology only requires a blood draw, providing patients with a new and powerful weapon in the fight against cancer.

Statistics:

The accuracy rate of the new liquid biopsy technology is 95% in detecting early colorectal cancer.
The accuracy rate of existing non-invasive detection methods for late-stage cancer is around 90%, but drops to less than 50% for early-stage cancer.
The amount of circulating free DNA (cfDNA) in the blood is often low in early stages of cancer, limiting the accuracy of existing detection methods.
RNA modification levels can reflect the state of an organism, with more active organisms having more frequent RNA modifications.

Sources:

https://www.cas.cn/kj/202507/t20250709_5075658.shtml
Nature Biotechnology (study was published in the latest issue)